Is ADMA Biologics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for ADMA Biologics, Inc. has moved from expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 24, an EV to EBITDA of 30.78, and a PEG ratio of 0.03, which suggests potential growth relative to its price.
In comparison with peers, ADMA Biologics has a fair valuation with a P/E of 18.56, while Protagonist Therapeutics, Inc. is considered very expensive with a P/E of 67.18. The company has also outperformed the S&P 500 significantly over the long term, with a 3-year return of 433.83% compared to the S&P 500's 81.19%, although it has underperformed in the short term.